PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjThe BMJ
 
BMJ. 1991 November 2; 303(6810): 1100–1104.
PMCID: PMC1671261

beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination.

Abstract

OBJECTIVE--To determine the effects of the beta 1 selective adrenoceptor blocker atenolol, the dihydropyridine calcium antagonist nifedipine, and the combination of atenolol plus nifedipine on objective and subjective measures of walking performance and foot temperature in patients with intermittent claudication. DESIGN--Randomised controlled double blind four way crossover trial. SETTING--Royal Hallamshire Hospital, Sheffield. SUBJECTS--49 patients (40 men) aged 39-70 with chronic stable intermittent claudication. INTERVENTIONS--Atenolol 50 mg twice daily; slow release nifedipine 20 mg twice daily; atenolol 50 mg plus slow release nifedipine 20 mg twice daily; placebo. Each treatment was given for four weeks with no washout interval between treatments. MAIN OUTCOME MEASURES--Claudication and walking distances on treadmill; skin temperature of feet as measured by thermistor and probe; blood pressure before and after exercise; subjective assessments of walking difficulty and foot coldness with visual analogue scales. RESULTS--Atenolol did not significantly alter claudication distance (mean change -6%; 95% confidence interval 1% to -13%), walking distance (-2%; 4% to -8%), or foot temperature. Nifedipine did not alter claudication distance (-4%; 3% to -11%), walking distance (-4%; 3% to -10%), or foot temperature. Atenolol plus nifedipine did not alter claudication distance but significantly reduced walking distance (-9%; -3% to -15% (p less than 0.003)) and skin temperature of the more affected foot (-1.1 degrees C; 0 to -2.2 degrees C (p = 0.05)). These effects on walking distance and foot temperature seemed unrelated to blood pressure changes. CONCLUSIONS--There was no evidence of adverse or beneficial effects of atenolol or nifedipine, when given singly, on peripheral vascular disease. The combined treatment, however, affected walking ability and foot temperature adversely. This may have been due to beta blockade plus reduced vascular resistance, which might also explain the reported adverse effects of pindolol and labetalol on claudication.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Kannel WB, Skinner JJ, Jr, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation. 1970 May;41(5):875–883. [PubMed]
  • Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J. 1978 May 27;1(6124):1379–1381. [PMC free article] [PubMed]
  • Ramsay LE. Intermittent claudication in hypertensive men. J R Coll Physicians Lond. 1979 Apr;13(2):100–102. [PubMed]
  • Frohlich ED, Tarazi RC, Dustan HP. Peripheral arterial insufficiency. A complication of beta-adrenergic blocking therapy. JAMA. 1969 Jun 30;208(13):2471–2472. [PubMed]
  • Rodger JC, Sheldon CD, Lerski RA, Livingstone WR. Intermittent claudication complicating beta-blockade. Br Med J. 1976 May 8;1(6018):1125–1125. [PMC free article] [PubMed]
  • Vale JA, Jefferys DB. Peripheral gangrene complicating beta-blockade. Lancet. 1978 Jun 3;1(8075):1216–1216. [PubMed]
  • Gokal R, Dornan TL, Ledingham JG. Peripheral skin necrosis complicating beta-blockage. Br Med J. 1979 Mar 17;1(6165):721–722. [PMC free article] [PubMed]
  • Fogoros RN. Exacerbation of intermittent claudication by propranolol. N Engl J Med. 1980 May 8;302(19):1089–1089. [PubMed]
  • Ingram DM, House AK, Thompson GH, Stacey MC, Castleden WM, Lovegrove FT. Beta-adrenergic blockade and peripheral vascular disease. Med J Aust. 1982 Jun 12;1(12):509–511. [PubMed]
  • Reichert N, Shibolet S, Adar R, Gafni J. Controlled trial of propranolol in intermittent claudication. Clin Pharmacol Ther. 1975 May;17(5):612–615. [PubMed]
  • Lepäntalo M, von Knorring J, Lindfors O, Scheinin TM. The effect of withdrawal of beta-adrenergic blockade on intermittent claudication. Angiology. 1983 Jun;34(6):401–411. [PubMed]
  • Bogaert MG, Clement DL. Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication. Eur Heart J. 1983 Mar;4(3):203–204. [PubMed]
  • Hiatt WR, Stoll S, Nies AS. Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation. 1985 Dec;72(6):1226–1231. [PubMed]
  • Svendsen TL, Jelnes R, Tønnesen KH. The effects of acebutolol and metoprolol on walking distances and distal blood pressure in hypertensive patients with intermittent claudication. Acta Med Scand. 1986;219(2):161–165. [PubMed]
  • Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet. 1987 Sep 19;2(8560):650–653. [PubMed]
  • Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol. 1988 Nov;26(5):569–576. [PMC free article] [PubMed]
  • Lewis P, Psaila JV, Davies WT, Morgan RH, Woodcock JP. Nifedipine in patients with peripheral vascular disease. Eur J Vasc Surg. 1989 Apr;3(2):159–164. [PubMed]
  • Aoki K, Kondo S, Mochizuki A, Yoshida T, Kato S, Kato K, Takikawa K. Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade. Am Heart J. 1978 Aug;96(2):218–226. [PubMed]
  • Findlay IN, Dargie HJ. The effects of nifedipine, atenolol and that combination on left ventricular function. Postgrad Med J. 1983;59 (Suppl 2):70–73. [PubMed]
  • Lewis RV, Jackson PR, Ramsay LE. Quantification of side-effects of beta-adrenoceptor blockers using visual analogue scales. Br J Clin Pharmacol. 1984 Sep;18(3):325–330. [PMC free article] [PubMed]
  • Lewis RV, Jackson PR, Ramsay LE. Side-effects of beta-adrenoceptor blocking drugs assessed by visual analogue scales. Br J Clin Pharmacol. 1985 Feb;19(2):255–257. [PMC free article] [PubMed]
  • Lorentsen E, Landmark K. The acute effects of nifedipine on calf and forefoot blood flow in patients with peripheral arterial insufficiency. Angiology. 1983 Jan;34(1):46–52. [PubMed]
  • McSorley PD, Warren DJ. Effects of propranolol and metoprolol on the peripheral circulation. Br Med J. 1978 Dec 9;2(6152):1598–1600. [PMC free article] [PubMed]
  • Lepäntalo M, Tötterman KJ. Effect of long-term beta-adrenergic-blockade on calf blood flow in hypertensive patients. Clin Physiol. 1983 Feb;3(1):35–42. [PubMed]
  • Kendall MJ. Are selective beta-adrenoceptor blocking drugs an advantage? J R Coll Physicians Lond. 1981 Jan;15(1):33–40. [PubMed]
  • Atterhög JH, Dunér H, Pernow B. Experience with pindolol, a betareceptor blocker, in the treatment of hypertension. Am J Med. 1976 May 31;60(6):872–876. [PubMed]
  • Lepäntalo M. Chronic effects of labetalol, pindolol, and propranolol on calf blood flow in intermittent claudication. Clin Pharmacol Ther. 1985 Jan;37(1):7–12. [PubMed]
  • Lepäntalo M. Chronic effects of metoprolol and methyldopa on calf blood flow in intermittent claudication. Br J Clin Pharmacol. 1984 Jul;18(1):90–93. [PMC free article] [PubMed]
  • GILLESPIE JA. The case against vasodilator drugs in occlusive vascular disease of the legs. Lancet. 1959 Dec 5;2(7110):995–997. [PubMed]

Articles from The BMJ are provided here courtesy of BMJ Publishing Group